3/4/2007 07:49 London Time
PARIS (AFX) - Sanofi-Aventis said that Switzerland''s regulatory body Swissmedic has approved anti-obesity drug Acomplia for sale in the country.
Sanofi-Aventis said the regulator has authorised the use of the drug for "for obese patients (Body Mass Index - BMI - greater than or equal to 30 kg/m2) or for overweight patients (BMI greater than or equal to 27 kg/m2) with at least one associated cardiovascular risk factor, after insufficient weight reduction following physical activity or alimentary adaptation.
The company last year received the regulatory approval of the European Union and has since started selling the drug in several countries, although with varying levels of reimbursement by health insurance schemes.
In the US, Sanofi-Aventis announced last week that the Food and Drug Administration (FDA) will review Acomplia on June 13.
Source:http://www.euro2day.gr |
